临床前研究显示,YL-17231 对多种 KRAS 突变类型具有更强的抑制作用,广泛适用于携带 KRAS G12C、G12D、G12V、G13D、G12R、G12A 等突变及 KRAS 野生型扩增的肿瘤,以及对 KRAS G12C 抑制剂产生耐药性的肿瘤。 JAB-23425 JAB-23425 作为广谱 KRAS 抑制剂,可同时抑制 KRAS 的活性及非活性状态,并对 HRAS、...
KRAS-G12D point mutation negatively correlated with PD-L1 level and secretion of chemokines CXCL10/CXCL11 that led to a decrease in CD8+ TILs, which in turn yielded an immunosuppressive TIME. The analysis of cell lines overexpressing
临床前研究结果显示:MRTX1133 能选择性与 KRAS G12D 突变体结合,在多种携带 KRAS G12D 突变的肿瘤细胞系中均显示出特异性抑制 KRAS 依赖的相关信号通路,并且MRTX1133 和 EGFR 单抗西妥昔单抗联合用药相比于单药能够抑制肿瘤细胞 pERK 和 pS6 的表达,显著提...
20. Sacher, A., LoRusso, P., Patel, M.R., Miller, W.H., Garralda, E., Forster, M.D., Santoro, A., Falcon, A., Kim, T.W., Paz-Ares, L., et al. (2023). Single-Agent Divarasib (GDC-6036) i...
Danysh, Brian P., Erin Y. Rieger, Deepankar K. Sinha, Caitlin V. Evers, Gilbert J. Cote, Maria E. Cabanillas, and Marie-Claude Hofmann. 2016. “Long-Term Vemurafenib Treatment Drives Inhibitor Resistance through a Spontaneous KRAS G12D Mutation in a BRAF V600E Papillary Thyroid Carcinoma ...
clinical use, and many questions remain to be answered, such as the mechanisms of resistance in this subtype of NSCLC, how to better utilize combination strategies with multiple treatment modalities, and whether KRASG12D inhibitors offer substantial efficacy in the treatment of advanced NSCLC ...
KRAS G12D mutation is one of the most prevalent subtypes in RAS mutant cancers. However, no results of KRAS G12D inhibitors from any clinical trials have been reported yet. HRS-4642 is a highly selective KRAS G12D inhibitor. Here, we report preliminary results of the dose escalation part...
名称:iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation 主办方:M.D. Anderson Cancer Center 合作方:National Cancer Institute (NCI) 适应症: KRAS NP_004976.2:p.G12D Metastatic Pancreatic Adenocarcinoma Pancreatic Ductal Adenocarcinoma ...
目前，针对KRAS G12C靶点的研究方兴未艾，而对KRAS G12D等其他靶点的探索以及泛RAS抑制剂的研发也已进入临床开发阶段。MRTX1133是Mirati Therapeutics研发的一款选择性非共价 KRAS G12D 抑制剂，目前已经获得了FDA 批准，获得新药临床试验申请批准，在 2023 年已经开始进入 I/II 期临床阶段。临床前研究结果显示：...
KRAS G12D mutation is one of the most prevalent subtypes in RAS mutant cancers. However, no results of KRAS G12D inhibitors from any clinical trials have been reported yet. HRS-4642 is a highly selective KRAS G12D inhibitor. Here, we report preliminary results of the dose escalation part...